All In Biotech

Drug Trial Radar · NCT00988065

Sugammadex Hypersensitivity Study (Study P06042)

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administrations of Sugammadex (SCH 900616) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 448 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

448

Actual

Start

Sep 6, 2009

Primary completion

Apr 13, 2010

Study completion Apr 13, 2010

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial was conducted to study the potential for hypersensitivity symptoms at the time of initial exposure to sugammadex and upon repeat exposure, since it was unknown whether the frequency or severity of hypersensitivity symptoms may worsen at repeat exposure over a prolonged period. In total 450 participants (all healthy subjects) were to be randomized to receive one of three study treatments: three repeated doses of either sugammadex 4 mg/kg, sugammadex 16 mg/kg, or placebo. Participants were to receive one dose of study treatment on Day 8, Day 36, and Day 78 of the study in order to determine the safety of each treatment dose.

Conditions

  • Hypersensitivity

Interventions

  • Placebo run-in doseDrug

    Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization

  • Sugammadex 4 mg/kgDrug

    Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study

  • Sugammadex 16 mg/kgDrug

    Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study

  • PlaceboDrug

    Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants With Adjudicated Hypersensitivity Signs/Symptoms, for Each Sugammadex Dose Group and Placebo.Time frame: Day 8, Day 36, and Day 78 of the study

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.